ACC 22: Findings from the VALOR-HCM Trial | Dr Milind Y Desai

Watch on Radcliffe Cardiology: www.radcliffecardiology.com/v...
In this short summary interview, Dr Milind Y Desai (Cleveland Clinic, Cleveland, OH, US) shares the findings from the VALOR-HCM trial (MyoKardia) (NCT04349072). This randomised, multicentre study was designed to assess the effect of mavacamten treatment on reducing the number of septal reduction therapy (SRT) procedures performed in subjects with symptomatic obstructive hypertrophic cardiomyopathy.
Discussion Points:
-Background of the Study
-Study Design & Selection of Patient Cohort
-Key Findings
-Effect on Clinical Practice
-Next Steps
-Take-home Messages
Recorded on-site ACC.22, Washington.
Interviewer: Mirjam Boros
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.